Forbes

The Taliban's restrictions on female education, plus the loss of international aid, mean that mothers are dying due to closed services.

States now have six more months before anyone loses Medicaid over the work rule. A physician explains how Nebraska’s early numbers show what they should do with the time.

Eldercare costs Americans far more than the price of care itself. From public funding to caregiver wages and lost income, here's where the money goes and why the burden keeps growing.

Many experts believe the US has lost status with the rest of the world as "personal freedom" has trumped public health and vaccination. Measles cases will keep growing.

A doctor explains the new prostate cancer screening guidelines, why they were updated, and why they are important.

The “Pilates After Dark” events that mix Pilates done outside traditional studios with various social activities may be part of broader meet-cute dating and IRL trends.

Open enrollment season for health insurance is the time to review how your current health insurance plan, circumstances, health and available options may have changed

With more flexible regulatory guidance and an administration that appears enthused about prospects for psychedelics, it’s possible we’ve entered a new era for research.

Melissa Etheridge, who received the 2026 Hope Award for Mental Health Advocacy, talked about the Etheridge Foundation's work in plant medicine for opioid use disorder.

WHO's 2026 Global Tuberculosis Report shows that over a million people died of TB in 2025, with worrisome drop in international donor funding

The Centers for Medicare and Medicaid Services final rule prevents manufacturers from resetting statutory drug price negotiation clocks through reformulations.

Novo president and chief executive officer Mike Doustdar talked about Ozempic, Wegovy, new GLP-1 medications, weight loss and obesity and the company's new rebrand

Healthsystems promise a doctor will catch AI errors. Studies show clinicians often follow wrong AI advice. A doctor explains when human review works and when it fails.

A once-daily oral peptide improved ulcerative colitis response and remission rates in a phase 2 trial, offering a potential alternative to injections or infusions.